These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1112 related items for PubMed ID: 8989263

  • 1. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [Abstract] [Full Text] [Related]

  • 5. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E.
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 7. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life.
    Aguiar-Oliveira MH, Gill MS, de A Barretto ES, Alcântara MR, Miraki-Moud F, Menezes CA, Souza AH, Martinelli CE, Pereira FA, Salvatori R, Levine MA, Shalet SM, Camacho-Hubner C, Clayton PE.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 9. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans.
    Olivecrona H, Hilding A, Ekström C, Barle H, Nyberg B, Möller C, Delhanty PJ, Baxter RC, Angelin B, Ekström TJ, Tally M.
    J Clin Endocrinol Metab; 1999 Feb; 84(2):553-60. PubMed ID: 10022415
    [Abstract] [Full Text] [Related]

  • 10. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P, Zwimpfer C, Zapf J, Schmid C.
    Acta Obstet Gynecol Scand; 2006 Feb; 85(8):900-5. PubMed ID: 16862465
    [Abstract] [Full Text] [Related]

  • 11. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 12. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, Jørgensen JO, Cuneo RC, Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L, Baxter RC, Basset EE, Sönksen PH.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [Abstract] [Full Text] [Related]

  • 13. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS, Toogood AA, Jones J, Clayton PE, Shalet SM.
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [Abstract] [Full Text] [Related]

  • 14. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
    Münzer T, Rosen CJ, Harman SM, Pabst KM, St Clair C, Sorkin JD, Blackman MR.
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment.
    Ferrante E, Giavoli C, Porretti S, Vassallo E, Ronchi CL, Lania AG, Beck-Peccoz P, Spada A.
    Horm Metab Res; 2006 May; 38(5):352-5. PubMed ID: 16718634
    [Abstract] [Full Text] [Related]

  • 16. GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake.
    Lange KH, Isaksson F, Rasmussen MH, Juul A, Bülow J, Kjaer M.
    Clin Endocrinol (Oxf); 2001 Jul; 55(1):77-86. PubMed ID: 11453955
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
    Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JO, Christiansen JS.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
    [Abstract] [Full Text] [Related]

  • 18. Decreased serum levels of acid-labile subunit in patients with anorexia nervosa.
    Fukuda I, Hotta M, Hizuka N, Takano K, Ishikawa Y, Asakawa-Yasumoto K, Tagami E, Demura H.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2034-6. PubMed ID: 10372706
    [Abstract] [Full Text] [Related]

  • 19. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
    Bannink EM, van Doorn J, Stijnen T, Drop SL, de Muinck Keizer-Schrama SM.
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
    [Abstract] [Full Text] [Related]

  • 20. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
    Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 56.